Koo,

I've posted a bunch on the alkaline phosphatase story already, so I'll just re-post for you to enjoy. So far, the data presented has been on the Phase 2 trials and the baseline BETonMACE data. They have not yet presented on the actual BETonMACE data. I recommend you take a look at the past ERA-EDTA symposia videos if you need some narration and background on the alkaline phosphatase story. Building evidence supports a connection amongst CVD, kidney disease and cognition, and it seems like alkaline phosphatase may be at the center of it all.

Apabetalone and Alkaline Phosphatase

Apabetalone Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk - ASN 2019 Poster

Apabetalone Lowers Serum Alkaline Phosphatase in CVD Patients With and Without CKD and Improves Cardiovascular Risk - ASN 2019 Poster

Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome - ASN 2019 Poster

ASN and AHA abstracts:

November 8th: 1048: Apabetalone Lowers Serum Alkaline Phosphatase in CVD Patients with and Without CKD and Improves Cardiovascular Risk

November 8th: 317: Association of Serum Alkaline Phosphatase with CKD and Cognitive Function in Patients with Diabetes and Acute Coronary Syndrome

November 9th: 782: Apabetalone Downregulates Alkaline Phosphatase and Improves Cardiovascular Risk

November 18th: ALP Levels Predict Adverse Cardiovascular Outcomes and Cognitive Impairment in High Risk Patients

Publications:

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease

Apabetalone downregulates factors and pathways associated with vascular calcification

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease

Benefit of Apabetalone on Plasma Proteins in Renal Disease

Apabetalone, A Selective Bromodomain And Extraterminal (BET) Protein Inhibitor, Reduces Serum FGF23 In Cardiovascular Disease and Chronic Kidney Disease Patients

ERA-EDTA 2018 and 2019 Symposia Presentations (full list here):

A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition

The role of ALP as predictor of CV events and vascular calcification in CKD

Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD

BETonMACE CKD Sub-study

BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60